NCT04685135 · OUTCOME

Overall Survival (OS)

Phase 3 Study of MRTX849 (Adagrasib) vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation · Source last updated 2026-08-11

This outcome was registered, but no numerical results were posted in the captured record.

Measure: Not reported
Unit: Not reported
Interval / dispersion: Not reported
Time frame: From randomization till death due to any cause (up to approximately 143 weeks)

What was measured

Overall survival is defined as the time from randomization to the date of death due to any cause.

Groups in this outcome

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Reported measurements

No numerical measurement classes were posted for this outcome. Missing is not zero.

Complete source fields

anticipated Posting Date: 2027-10
denom Units Selected: Participants
description: Overall survival is defined as the time from randomization to the date of death due to any cause.
reporting Status: NOT_POSTED
time Frame: From randomization till death due to any cause (up to approximately 143 weeks)
title: Overall Survival (OS)
type: SECONDARY

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice